A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Uveal MelanomaOcular Melanoma
Interventions
DRUG

roginolisib

rognolisib

DRUG

Investigator choice of standard therapy

Investigator will choose the most appropriate treatment standardly given to patients

Trial Locations (16)

15706

NOT_YET_RECRUITING

Complejo Hospitalario Universitario de Santiago - CHUS, Santiago de Compostela

20089

NOT_YET_RECRUITING

IRCCS Istituto Clinico Humanitas, Rozzano

28046

NOT_YET_RECRUITING

Hospital Universitario La Paz, Madrid

35128

NOT_YET_RECRUITING

IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera, Padua

46014

NOT_YET_RECRUITING

Consorcio Hospital General Universitario de València - CHGUV, Valencia

53100

RECRUITING

A.O.U.S. Santa Maria delle Scotte, Siena

70124

RECRUITING

SSD Tumori Rari e Melanoma Viale Orazio Flacco, Bari

80131

NOT_YET_RECRUITING

"IRCSS National Cancer Institute, G.Pascale Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative", Napoli

08908

RECRUITING

Institut Catala d'Oncologia - ICO L'Hospitalet, Barcelona

Unknown

RECRUITING

Hospital Universitario Virgen Macarena, University of Seville, Seville

HA6 2RN

RECRUITING

East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre), Northwood

CH63 4JH

NOT_YET_RECRUITING

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

G12 0YN

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde), Glasgow

NW1 2PG

RECRUITING

University College London Hospital NHS, London

SW3 6JJ

RECRUITING

Royal Marsden Hospital, London

SO16 6YD

RECRUITING

University Hospital Southampton NHS Foundation, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

iOnctura

INDUSTRY

NCT06717126 - A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter